20 Nov, 2023 01:12 PM
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that it has received its FY202...read more
27 Oct, 2023 06:38 PM
Pursuant to ASX Listing Rule 3.13.2, Altech Chemicals Limited (Company) (ASX: ATC) advises that all Resolutions put to shareholders at the Company’s Annual General Meeting held on 27 October 2...read more
27 Oct, 2023 12:42 PM
MELBOURNE, AUSTRALIA 27 October 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treat...read more
12 Oct, 2023 09:29 AM
Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting a validated target, Claudin 18.2 (CLDN18.2), which is...read more